Bayer AG stock (DE000BAY0017): S&P affirms BBB rating with negative outlook

S&P Global Ratings affirmed Bayer AG's 'BBB' long-term foreign currency credit rating on May 8, 2026, maintaining a negative outlook amid ongoing challenges.

S&P Global Ratings affirmed Bayer AG's 'BBB' Foreign Currency LT credit rating on May 8, 2026, with a negative outlook, reflecting persistent pressures in its pharmaceuticals and crop science segments. The affirmation comes as Bayer navigates litigation risks and market headwinds, according to Cbonds as of May 8, 2026.

Bayer AG shares traded at $10.86 on OTCQX on May 8, 2026, up 0.09% from the prior close, per StockInvest.us as of May 8, 2026. On the home exchange, the stock closed at 37.09 EUR on May 8, 2026, according to Euronext data.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bayer AG
• Sector/industry: Pharmaceuticals and crop science
• Headquarters/country: Germany
• Core markets: Global, with strong US presence
• Key revenue drivers: Pharmaceuticals, crop protection
• Home exchange/listing venue: Frankfurt (BAYN.DE)
• Trading currency: EUR

Bayer AG: core business model

Bayer AG operates as a global life sciences company with three main divisions: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals segment focuses on prescription drugs in cardiology, oncology, and women's health, while Crop Science provides seeds, pesticides, and digital farming solutions. Headquartered in Leverkusen, Germany, Bayer generates significant revenue from the US market, making it relevant for American investors tracking healthcare and agriculture exposure.

The company's business model emphasizes innovation through R&D investment, with over €5 billion spent annually as reported in its 2024 annual report published March 2025. Bayer's US ADR (BAYRY) offers retail investors easy access to its diversified portfolio.

Main revenue and product drivers for Bayer AG

Pharmaceuticals account for about 40% of revenue, led by blockbuster drugs like Xarelto (rivaroxaban) for blood clot prevention and Eylea (aflibercept) for eye diseases. Crop Science contributes around 35%, driven by herbicides like Roundup and seeds for major crops. Consumer Health, now partially divested, previously bolstered margins with brands like Claritin.

In Q4 2025, Bayer Cropscience India reported net sales of Rs 1,106.20 crore, up 4.66% year-over-year, per Moneycontrol as of Feb 25, 2026. This reflects resilience in agchem amid global demand.

Industry trends and competitive position

Bayer competes with Pfizer, Novartis in pharma and Corteva, Syngenta in crop science. Trends like precision agriculture and gene therapies favor Bayer's pipeline, including recent acquisitions. The company bolstered its ophthalmology portfolio with the Perfuse Therapeutics deal, valued up to $2.45 billion including $300 million upfront, targeting glaucoma treatments.

Why Bayer AG matters for US investors

Bayer's US revenues exceed 30% of total sales, with key products approved by the FDA and listed on OTCQX. Exposure to US agriculture via Crop Science and pharma blockbusters provides a hedge against domestic market shifts, appealing to investors seeking international diversification.

Conclusion

The S&P rating affirmation underscores Bayer AG's stable credit profile despite a negative outlook tied to litigation and segment challenges. Recent M&A activity signals pipeline growth, while steady sales in key units support operations. US investors may monitor upcoming earnings for clarity on guidance and strategic execution.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.